Stock detail
Biogen (BIIB) stock price, chart, and key data
View Biogen stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Biogen
BIIB · XNAS
$249.65
+2.29%
+$5.60
Pre-market $259.45 (+3.93%)
Key metrics
52-week range
$14.75 - $30.00
Close price
$244.05
Market cap
$36.1B
P/E ratio
-1,743.21
Beta
1.77
About the company
Biogen Inc.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$256
17
Buy
/ 24
Recent calls
10/29/2026
Argus Research
Jasper Hellweg
Buy · Price target $280
10/29/2026
UBS
Michael Yee
Buy · Price target $300
10/29/2026
Morgan Stanley
Terence Flynn
Hold · Price target $238
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app